These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7847031)

  • 1. [Anagrelide--new antiplatelet drug].
    Robak T; Treliński J; Hołub A
    Acta Haematol Pol; 1994; 25(4):309-15. PubMed ID: 7847031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia.
    Spencer CM; Brogden RN
    Drugs; 1994 May; 47(5):809-22. PubMed ID: 7520859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
    Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
    Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
    Espasandin YR; Glembotsky AC; Grodzielski M; Lev PR; Goette NP; Molinas FC; Marta RF; Heller PG
    J Thromb Haemost; 2015 Apr; 13(4):631-42. PubMed ID: 25604267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anagrelide: a novel agent for the treatment of myeloproliferative disorders.
    Pescatore SL; Lindley C
    Expert Opin Pharmacother; 2000 Mar; 1(3):537-46. PubMed ID: 11249536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anagrelide: 20 years later.
    Emadi A; Spivak JL
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
    Penninga E; Jensen BA; Hansen PB; Clausen NT; Mourits-Andersen T; Nielsen OJ; Hasselbalch HC
    Clin Lab Haematol; 2004 Oct; 26(5):335-40. PubMed ID: 15485463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
    N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.
    Mazur EM; Rosmarin AG; Sohl PA; Newton JL; Narendran A
    Blood; 1992 Apr; 79(8):1931-7. PubMed ID: 1562721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL; Bertolino G; Noris P; Ascari E
    Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
    Thiele J; Kvasnicka HM; Schmitt-Gräff A
    Pathologe; 2002 Nov; 23(6):426-32. PubMed ID: 12436295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anagrelide--a new drug to reduce platelets in myeloproliferative diseases].
    Bennett M
    Harefuah; 1999 May; 136(9):717-20. PubMed ID: 10955097
    [No Abstract]   [Full Text] [Related]  

  • 14. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
    Thiele J; Kvasnicka HM; Fuchs N; Brunnbauer K; Volkwein N; Schmitt-Graeff A
    Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of anagrelide on human megakaryocytopoiesis.
    Solberg LA; Tefferi A; Oles KJ; Tarach JS; Petitt RM; Forstrom LA; Silverstein MN
    Br J Haematol; 1997 Oct; 99(1):174-80. PubMed ID: 9359521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
    Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anagrelide treatment in myeloproliferative disorders.
    Birgegard G
    Semin Thromb Hemost; 2006 Apr; 32(3):260-6. PubMed ID: 16673280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.
    Wang G; Franklin R; Hong Y; Erusalimsky JD
    Br J Pharmacol; 2005 Oct; 146(3):324-32. PubMed ID: 16041400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.